MARKET

BPTH

BPTH

Bio-Path Hldgs Inc
NASDAQ
3.050
-0.100
-3.17%
After Hours: 3.010 -0.04 -1.31% 18:47 04/12 EDT
OPEN
3.100
PREV CLOSE
3.150
HIGH
3.240
LOW
3.000
VOLUME
22.78K
TURNOVER
0
52 WEEK HIGH
44.80
52 WEEK LOW
3.000
MARKET CAP
2.30M
P/E (TTM)
-0.0907
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at BPTH last week (0401-0405)?
Weekly Report · 5d ago
Stocks to Watch: Kura Sushi, Bio-Path Holdings
Kura Sushi's sales rose sharply in the fiscal second quarter. The sushi restaurant chain slightly upped its full-year guidance for revenue. Shares rose 7.1% to $111.25 after-hours. Bio-Path Holdings said it reached a deal for an at-the-market share offering.
Dow Jones · 04/04 23:24
Bio-Path Holdings shares sink 6% after deal for at-the-market offering
MarketWatch · 04/04 23:14
Bio-Path Holdings Shares Sink 6.3% on At-The-Market Offering
Bio-Path Holdings shares are down 6.3% in late trading. The company says it has reached a deal for an at-the-market share offering. Shares of the company are down 54% in the last year. The stock was down about 6.5% late Thursday. The offering will be for up to $2 million.
Dow Jones · 04/04 22:32
Bio Path Holdings Said May Offer And Sell Up To $2M Of Common Stock From Time To Time Through HC Wainwright; Entered Into At Market Offering Agreement Relating To Shares Of Common Stock Offered By Prospectus Supplement
Benzinga · 04/04 20:40
BIO PATH HOLDINGS INC - ENTERED INTO AT MARKET OFFERING AGREEMENT RELATING TO SHARES OF COMMON STOCK OFFERED BY PROSPECTUS SUPPLEMENT
Reuters · 04/04 20:34
Bio-Path Holdings Announces 2024 Clinical and Operational Progress
TipRanks · 04/02 20:23
BIO-PATH HOLDINGS PROVIDES 2024 CLINICAL AND OPERATIONAL UPDATE
Reuters · 04/02 11:00
More
About BPTH
Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.

Webull offers Bio Path Holdings Inc stock information, including NASDAQ: BPTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BPTH stock methods without spending real money on the virtual paper trading platform.